OTCPK:SCIE

Stock Analysis Report

Executive Summary

SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has SpectraScience's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

9900.0%

SCIE

-0.003%

US Medical Equipment

1.3%

US Market


1 Year Return

0%

SCIE

11.9%

US Medical Equipment

5.9%

US Market

Return vs Industry: SCIE underperformed the US Medical Equipment industry which returned 11.9% over the past year.

Return vs Market: SCIE underperformed the US Market which returned 5.9% over the past year.


Shareholder returns

SCIEIndustryMarket
7 Day9900.0%-0.003%1.3%
30 Day0%-3.0%-1.9%
90 Day0%-0.6%-1.8%
1 Year0%0%12.8%11.9%8.3%5.9%
3 Year-97.4%-97.4%69.6%64.5%45.6%36.2%
5 Year-99.5%-99.5%129.6%104.0%66.1%47.9%

Price Volatility Vs. Market

How volatile is SpectraScience's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is SpectraScience undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether SpectraScience is trading at an attractive price based on the cash flow it is expected to produce in the future. But as SpectraScience has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of SCIE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through SpectraScience regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is SpectraScience forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SpectraScience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of SCIE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access SpectraScience's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has SpectraScience performed over the past 5 years?

17.0%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, SpectraScience has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is SpectraScience's financial position?


In this section we usually analyse SpectraScience's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. SpectraScience has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of SCIE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when SpectraScience's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is SpectraScience's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SCIE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SCIE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SCIE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SCIE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SCIE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of SpectraScience's salary, the management and board of directors tenure and is there insider trading?

9.4yrs

Average board tenure


CEO

Mike Oliver (71yo)

8.9yrs

Tenure

US$325,000

Compensation

Mr. Michael P. Oliver, also known as Mike, has been the President and Chief Executive Officer of Spectrascience Inc. since November 29, 2010 and has been its Chief Operating Officer since July 06, 2013. Si ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Mike's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Mike's compensation with company performance.


Board Age and Tenure

9.4yrs

Average Tenure

77yo

Average Age

Experienced Board: SCIE's board of directors are considered experienced (9.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Lowell Giffhorn (72yo)

    CFO & Secretary

    • Tenure: 6yrs
    • Compensation: US$90.00k
  • Mike Oliver (71yo)

    CEO, President

    • Tenure: 8.9yrs
    • Compensation: US$325.00k

Board Members

  • F. Townsen (86yo)

    Independent Director

    • Tenure: 10.3yrs
    • Compensation: US$1.37k
  • Rand Mulford (75yo)

    Independent Director

    • Tenure: 4.8yrs
  • Mark McWilliams (62yo)

    Chairman

    • Tenure: 9yrs
    • Compensation: US$1.48k
  • Tommy Thompson (77yo)

    Chairman of the Advisory Board

    • Tenure: 9.8yrs
    • Compensation: US$95.57k
  • Stan Pappelbaum (81yo)

    Independent Director

    • Tenure: 13.3yrs
    • Compensation: US$1.02k
  • Mike Oliver (71yo)

    CEO, President

    • Tenure: 8.9yrs
    • Compensation: US$325.00k
  • Sheldon Miller (83yo)

    Director

    • Tenure: 9.4yrs
    • Compensation: US$1.50k

Company Information

SpectraScience, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SpectraScience, Inc.
  • Ticker: SCIE
  • Exchange: OTCPK
  • Founded: 1983
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$4.923k
  • Shares outstanding: 4.92b
  • Website: https://www.spectrascience.com

Number of Employees


Location

  • SpectraScience, Inc.
  • 11568 Sorrento Valley Road
  • Suite 11
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SCIEOTCPK (Pink Sheets LLC)YesCommon StockUSUSDAug 2004

Biography

SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, E ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 23:51
End of Day Share Price2019/10/14 00:00
Earnings2017/09/30
Annual Earnings2016/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.